These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38874212)

  • 1. Lipid lowering for prevention of venous thromboembolism: a network meta-analysis.
    Farmakis IT; Christodoulou KC; Hobohm L; Konstantinides SV; Valerio L
    Eur Heart J; 2024 Jun; ():. PubMed ID: 38874212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis.
    Khan SU; Yedlapati SH; Lone AN; Hao Q; Guyatt G; Delvaux N; Bekkering GET; Vandvik PO; Riaz IB; Li S; Aertgeerts B; Rodondi N
    BMJ; 2022 May; 377():e069116. PubMed ID: 35508321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. More- Versus Less-Intensive Lipid-Lowering Therapy.
    Toyota T; Morimoto T; Yamashita Y; Shiomi H; Kato T; Makiyama T; Nakagawa Y; Saito N; Shizuta S; Ono K; Kimura T
    Circ Cardiovasc Qual Outcomes; 2019 Aug; 12(8):e005460. PubMed ID: 31412729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of negative control outcomes to assess the comparability of patients initiating lipid-lowering therapies.
    Levintow SN; Orroth KK; Breskin A; Park AS; Flores-Arredondo JH; Dluzniewski P; Navar AM; Sørensen HT; Brookhart MA
    Pharmacoepidemiol Drug Saf; 2022 Apr; 31(4):383-392. PubMed ID: 34894377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PCSK9 Inhibitors and Ezetimibe Monotherapy in Patients Not Receiving Statins: A Meta-Analysis of Randomized Trials.
    Benhuri B; Ueyama H; Takagi H; Briasoulis A; Kuno T
    Curr Vasc Pharmacol; 2021; 19(4):390-397. PubMed ID: 32767943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guideline LDL-C Threshold Achievement in Acute Myocardial Infarction Patients: A Real-World Evidence Study Demonstrating the Impact of Treatment Intensification with PCSK9i.
    Mackinnon ES; Har B; Champsi S; Wani RJ; Geyer L; Shaw E; Farris MS; Anderson TJ
    Cardiol Ther; 2023 Jun; 12(2):327-338. PubMed ID: 36656500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Low-Density Lipoprotein Cholesterol (LDL-C) Goal Achievement and Lipid-Lowering Therapy in the Patients With Coronary Artery Disease With Different Renal Functions.
    Zhang S; Li ZF; Shi HW; Zhang WJ; Sui YG; Li JJ; Dou KF; Qian J; Wu NQ
    Front Cardiovasc Med; 2022; 9():859567. PubMed ID: 35620524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Lipid-Lowering Drugs of Different Intensity on Clinical Outcomes: A Systematic Review and Network Meta-Analysis.
    Ma W; Pan Q; Pan D; Xu T; Zhu H; Li D
    Front Pharmacol; 2021; 12():713007. PubMed ID: 34744709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.
    Zhan S; Tang M; Liu F; Xia P; Shu M; Wu X
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012502. PubMed ID: 30480766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Between Intensity of Low-Density Lipoprotein Cholesterol Reduction With Statin-Based Therapies and Secondary Stroke Prevention: A Meta-analysis of Randomized Clinical Trials.
    Lee M; Cheng CY; Wu YL; Lee JD; Hsu CY; Ovbiagele B
    JAMA Neurol; 2022 Apr; 79(4):349-358. PubMed ID: 35188949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid lowering therapy in primary and secondary prevention in Austria: are LDL-C goals achieved? : Results from the DA VINCI study.
    Siostrzonek P; Brath H; Zweiker R; Drexel H; Hoelzl R; Hemetsberger M; Ray KK
    Wien Klin Wochenschr; 2022 Apr; 134(7-8):294-301. PubMed ID: 34870742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
    Schmidt AF; Pearce LS; Wilkins JT; Overington JP; Hingorani AD; Casas JP
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011748. PubMed ID: 28453187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is lipid lowering therapy an independent risk factor for venous thromboembolism? A population-based case-control study.
    Ashrani AA; Barsoum MK; Crusan DJ; Petterson TM; Bailey KR; Heit JA
    Thromb Res; 2015 Jun; 135(6):1110-6. PubMed ID: 25891841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.
    Virani SS; Kennedy KF; Akeroyd JM; Morris PB; Bittner VA; Masoudi FA; Stone NJ; Petersen LA; Ballantyne CM
    Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e004652. PubMed ID: 29748356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of Venous Thromboembolism with Statins: Evidence Gathered via a Network Meta-analysis.
    Birdal O; Saygı M; Doğan R; Tezen O; Karagöz A; Tanboğa İH
    Balkan Med J; 2023 Sep; 40(5):324-332. PubMed ID: 37519020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis.
    Lipinski MJ; Benedetto U; Escarcega RO; Biondi-Zoccai G; Lhermusier T; Baker NC; Torguson R; Brewer HB; Waksman R
    Eur Heart J; 2016 Feb; 37(6):536-45. PubMed ID: 26578202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statins and primary prevention of venous thromboembolism: a systematic review and meta-analysis.
    Kunutsor SK; Seidu S; Khunti K
    Lancet Haematol; 2017 Feb; 4(2):e83-e93. PubMed ID: 28089655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is the lower risk of venous thromboembolism with statins related to low-density-lipoprotein reduction? A network meta-analysis and meta-regression of randomised controlled trials.
    Zaccardi F; Kunutsor SK; Seidu S; Davies MJ; Khunti K
    Atherosclerosis; 2018 Apr; 271():223-231. PubMed ID: 29524865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Effects of Statin Dose, Lipophilicity, and Combination of Statins plus Ezetimibe on Circulating Oxidized Low-Density Lipoprotein Levels: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Jamialahmadi T; Baratzadeh F; Reiner Ž; Simental-Mendía LE; Xu S; Susekov AV; Santos RD; Sahebkar A
    Mediators Inflamm; 2021; 2021():9661752. PubMed ID: 34526854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interventions for implementation of thromboprophylaxis in hospitalized patients at risk for venous thromboembolism.
    Kahn SR; Morrison DR; Diendéré G; Piché A; Filion KB; Klil-Drori AJ; Douketis JD; Emed J; Roussin A; Tagalakis V; Morris M; Geerts W
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD008201. PubMed ID: 29687454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.